EHMSG 2021 Virtual Conference | e-Poster Presentations

Electronic Poster Round 1: Diagnosis of Helicobacter infection

 

P01.01
Prevalence of clarithromycin resistant strains in Helicobacter pylori positive patients after COVID-19
Presenting Author: Valeriy Kryvy, Simferopol, Russian Federation

 

P01.02
New rapid H.pylori blood test based on FLID and Cag A antibodies detection
Presenting Author: Christian Schulz, Munich, Germany

 

P01.03
The frequency of false positive Helicobacter urease tests during the routine endoscopy is negligible low
Presenting Author: Alexander Link, Magdeburg, Germany

 

P01.04
Comparative evaluation of Helicobacter pylori susceptibility testing methods to optimize routine analysis.
Presenting Author: Véronique MIENDJE DEYI, Brussels, Belgium

 

P01.05
H. pylori diagnostic tests used in naïve patients: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Ignasi Puig, Manresa, Spain

 

P01.06
The patient experience and clinical efficacy of a novel virtual C13UBT service at an Irish tertiary referral center during the Covid 19 pandemic.
Presenting Author: Sandeep Sihag, Dublin, Ireland

 

P01.07
Molecular diagnosis of Helicobacter pylori: validation of Allplex™ H. pylori and ClariR Assay
Presenting Author: Pierre Bogaerts, Yvoir, Belgium

 

P01.08
Comparison of histological examination and semi-quantitative detection of H. pylori infection: a pilot study.
Presenting Author: Elena Kolomina, St. Petersburg, Russian Federation

P01.09
Helicobacter pylori infection -related metabolic and gastric mucosa pre-malignant histological parameters in Swiss bariatric patients
Presenting Author: Michael Doulberis, Aarau, Switzerland

P01.10
The prevalence of Helicobacter pylori infection among dyspeptic patients in Northwestern Romania: a decreasing epidemiological trend in the last 30 years
Presenting Author: Alexandra Corojan, Cluj-Napoca, Romania

P01.11
Molecular diagnosis and histopathology: is there a difference between the methods for detecting Helicobacter pylori in severe and non-severe esogastroduodenal lesions?
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P01.12
Two types of ammonium breath test for detection of H. pylori infection
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

P01.13
Accuracy of gastric biopsy-based methods for diagnosis of Helicobacter pylori infection in symptomatic Vietnamese children.
Presenting Author: Tu Nguyen Cam, Ho Chi Minh City, Viet Nam


Electronic Poster Round 2: Treatment of Helicobacter infection

 

P02.01
Efficacy of vonoprazan-based dual therapy and vonoprazan-based triple therapy for Helicobacter pylori eradication: A prospective randomized study
Presenting Author: Sarita Ratana-Amornpin, Pathum Thani, Thailand

P02.02
A double-blind, placebo-controlled, multicenter study of the efficacy and safety of alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis, associated with H. pylori
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

P02.03
Tackling Helicobacter pylori infection by a pre-clinical prophylactic vaccination strategy
Presenting Author: Verena Friedrich, Munich, Germany

P02.04
A multicenter study on the past use of metronidazole and the success rate of eradication of Helicobacter pylori
Presenting Author: Younghee Choe, Seoul, Korea, Republic of

P02.05
Treatments after failed therapy in H. pylori infected children in Europe: Results of the EuroPedHp Registry
Presenting Author: Thu Giang Le Thi, München, Germany

P02.06
First-line empirical therapy for the eradication of H. pylori in Italy: data on effectiveness from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.07
Second-line empirical therapy for the eradication of H. pylori in Italy: data on effectiveness from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.08
Quadruple hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance country: the importance of a close medical-patient relationship
Presenting Author: Catarina Correia, Coimbra, Portugal

P02.09
An observational real-life study evaluating the efficacy of 10 and 14-days Concomitant therapy supplemented with probiotics for H pylori eradication in naïve patients in a high Clarithromycin and Metronidazole resistance area
Presenting Author: Kateryna Priadko, Napoli, Italy

P02.10
Primary antimicrobial resistance trend in Italian H. pylori naïve patients between 2013-2020: analysis of the European Registry on H. pylori Management (Hp-EuReg
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.11
Vonoprazan-based Dual Therapy and High-dose PPI Dual Regimens for H. pylori Eradication: A Comparison of the Available Data
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.12
First-line empirical H. pylori eradication therapy in Europe: Results from 30,000 cases of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.13
Empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2020: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.14
Empirical second-line treatments in Europe: Results from the European Registry on H. pylori Management (Hp-EuReg
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.15
Experience with single capsule bismuth quadruple therapy in 5,000 patients from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.16
Bismuth quadruple three-in-one single capsule: 3 or 4 times daily? Sub-analysis of the Spanish data of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Ángeles Pérez-Aísa*, Marbella, Spain

P02.17
Antibiotic resistance trends of Helicobacter pylori naïve patients in the period 2013-2020: analysis of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luis Bujanda, San Sebastián, Spain

P02.18
Experience with rifabutin-containing therapy in 426 patients from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.19
Non-bismuth quadruple concomitant treatment for H. pylori eradication: systematic review and meta-analysis
Presenting Author: Olga Nyssen, Madrid, Spain

P02.20
Eradication of Helicobacter pylori: meta-analysis-based or registry-based? A personal view.
Presenting Author: György Buzás, Budapest, Hungary

P02.21
Efficacy and safety of vonoprazan-based quadruple regimens for the eradication of Helicobacter pylori in Chinese patients with peptic ulcer: a pooled analysis of two phase III trials
Presenting Author: Xiaohua Hou, Wuhan, China

P02.22
Exploring the potential of bio-active components of Morinda citrifolia and its interaction with the Helicobacter pylori oncogenic protein CagA
Presenting Author: Priyanshu Pandey, Durgapur, India

P02.23
Gellan Gum hydrogels as a pH-responsive system to control the gastric delivery of highly effective antimicrobial microspheres against Helicobacter pylori
Presenting Author: Diana Fonseca, Porto, Portugal

P02.24
Comparative efficacy of eradication triple, sequential therapy and quadruple-therapy in patients after COVID-19
Presenting Author: Valeriy Kryvy, Simferopol, Russian Federation

P02.25
Effective eradication regimen and duration according to the results of clarithromycin susceptibility of Helicobacter pylori.
Presenting Author: Byung-Wook Kim, Incheon, Korea, Republic of

P02.26
Characteristics of empirical first- and second-line treatment prescribed between 2013-2020:Italian data from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.27
Tuning up nanostructured lipid carriers for specific Helicobacter pylori eradication: effect of size, charge and protein corona
Presenting Author: Rute Chitas, Porto, Portugal

P02.28
PPI-amoxicillin dual therapy four times daily is superior to guidelines-recommended regimens in the Helicobacter pylori eradication therapy: a systematic review & meta-analysis
Presenting Author: Cailing Li, Beijing, China

P02.29
Comparison of the reading of Clarithromycin E-test on Helicobacter Pylori by eye and with microscope
Presenting Author: Melodi Yusibova, København Ø, Denmark

P02.30
Addition of Saccharomyces boulardii to standard triple therapy in eradication of H. pylori: adverse events and compliance
Presenting Author: Olga Sjomina, Riga, Latvia

P02.31
Production of biofilm as a feature positively correlated with clarithromycin resistance in Helicobacter pylori
Presenting Author: Paweł Krzyżek, Wrocław, Poland

P02.32
Assessment of First-Line Treatment in Greece: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg).
Presenting Author: Theodore Rokkas, Athens, Greece

P02.33
Inhibitors of carbonic anhydrases as anti-Helicobacter pylori agents
Presenting Author: Rossella Grande, Chieti, Italy

P02.34
Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β
Presenting Author: Natalya Bakulina, Saint Petersburg, Russian Federation

P02.35
Development of new synthetic surfactants with anti-Helicobacter effect
Presenting Author: Elena Ermolenko, Saint-Petersburg, Russian Federation

P02.36
Evaluation of first-line bismuth containing 7-day quintet therapy for Helicobacter pylori eradication
Presenting Author: Yeji Choi, Seongnam-si, Korea, Republic of

P02.37
Adjuvant therapy with eupatilin improves the state of gastric mucosa in patients with H.pylori-associated chronic gastritis and diabetes mellitus type 2
Presenting Author: Igor Skrypnyk, Poltava, Ukraine

P02.38
Treatment and diagnosis of Helicobacter infection in Ukraine: successes and mistakes
Presenting Author: Yana Nikiforova, Kharkiv, Ukraine

P02.39
Metronidazole susceptibility testing for Helicobacter pylori isolates: comparing agar dilution method & Epsilomete test
Presenting Author: Xueli Tian, Beijing, China

P02.40
Comparison of the success rate of eradication of helicobacter pylori between hemodialysis patients and non-hemodialysis patients
Presenting Author: Seung Han Kim, Seoul, Korea, Republic of

P02.41
Helicobacter pylori & primary antibiotic resistance in the region of northeastern Romania
Presenting Author: Elena Popovici, Bacau, Romania


Electronic Poster Round 3: Gastric cancer

P03.01
Proteomic signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer
Presenting Author: Xue Li, Beijing, China

P03.02
Current smoking and H. pylori status is associated with precancerous lesions ,,missed” by serologic pepsinogen testing
Presenting Author: Danute Razuka-Ebela, Riga, Latvia

P03.03
Estrogen and Helicobacter pylori CagA may induce stem cell and epithelial mesenchymal transition phenotype in diffuse type gastric adenocarcinomas
Presenting Author: Seungkyung Kang, Seoul, Korea, Republic of

P03.04
Leukaemia Inhibitory Factor signalling for targeting Cancer Stem Cells in gastric adenocarcinoma
Presenting Author: Lornella Seeneevassen, Bordeaux, France

P03.05
Does microbial lactate play a role in gastric adenocarcinoma?
Presenting Author: Karla Vinasco-Pacheco, Sydney, Australia

P03.06
Reprograming of gastric epithelial cells towards precancerogenic and proinvasive phenotype by secretome of Helicobacter pylori-activated fibroblasts
Presenting Author: Tomasz Brzozowski, Cracow, Poland

P03.07
Putative impact of CagA protein on DNA damage repair machinery during Helicobacter pylori infection
Presenting Author: Eleftherios Kontizas, Athens, Greece

P03.08
Ex-vivo profiling of volatile organic compounds released from gastric cancer and non-cancerous tissue
Presenting Author: Daria Slefarska, Kielce, Poland

P03.09
The role of the nonspecific immunity in the progression of gastric cancer associated with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P03.10
Role of Claudin Proteins for Prediction of Lymphatic or Lymph Node Invasion among Submucosal-Invasive Early Gastric Cancer
Presenting Author: Moon Kyung Joo, Seoul, Korea, Republic of

P03.11
Reasons for refusing further endoscopic surveillance in patients with diagnosed precancerous gastric lesions
Presenting Author: Laura Rotberga, Riga, Latvia

P03.12
Periodontal disease, gingivitis, periodontitis, tooth loss & gastric adenocarcinoma: systematic review.
Presenting Author: Francisco Aguiar, São Paulo, Brazil

P03.13
Findings from the surveillance upper endoscopies in patients with gastric mucosal dysplasia at the baseline
Presenting Author: Laura Rotberga, Riga, Latvia

P03.14
Changes in lipid peroxidation and antioxidant protection in chronic atrophic gastritis and gastric cancer associated with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P03.15
Evaluation of the glutathione part of antioxidant protection in the development of atrophy in chronic gastritis and gastric cancer associated with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P03.16
Polyphenols Intake and Gastric Cancer: A quick review that precedes a case-control study in the Amazon region of Brazil
Presenting Author: Marcela Fagundes, São Paulo, Brazil

 

Electronic Poster Round 4: Helicobacter infection - pathogenesis and host response

 

P04.01
Helicobacter pylori upregulate epithelial cortactin expression in a CagA- and JNK-dependent manner
Presenting Author: Steffen Backert, Erlangen, Germany

P04.02
Helicobacter pylori PqqE protease cleaves junctional adhesion molecule A to disrupt tight junction functions
Presenting Author: Ceu Figueiredo, Porto, Portugal

P04.03
Effect of Helicobacter pylori eradication on the recurrence of gastric cancer after endoscopic submucosal dissection
Presenting Author: Jong-Jae Park, Seoul, Korea, Republic of

P04.04
Comprehensive integration of genome-wide association and gene expression studies reveals novel gene signatures for Helicobacter-induced gastric disease and potential therapeutic targets
Presenting Author: Mohamed Tarek Badr, Freiburg, Germany

P04.05
Inhibition of Polycomb Repressive Complex 2 expression and function by Helicobacter pylori.
Presenting Author: Rebecca FitzGerald, Dublin, Ireland

P04.06
Helicobacter pylori infection provides proangiogenic conditions in an experimental model of vascular endothelial cells
Presenting Author: Paulina Rusek-Wala, Lodz, Poland

P04.07
Helicobacter pylori infection, distribution of dupA virulence gene and associated clinical outcomes: the situation in Central West Brazil.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P04.08
Expression of apoptosis and proliferation proteins by the cells of inflammatory infiltrate of gastric lamina propria in patients with peptic ulcer disease
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

P04.09
Revisited role of Helicobacter pylori cagPAI, CagA, VacA and GGT in apoptosis during infection of gastric epithelial cells
Presenting Author: Steffen Backert, Erlangen, Germany

P04.10
Local cytokine status in Helicobacter pylori infection
Presenting Author: Guzel Isaeva, Kazan, Russian Federation

P04.11
Analysis of the Helicobacter pylori vacA virulence gene in dyspeptic patients
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P04.12
Searching for cross-reacting antibodies produced during Helicobacter pylori infection in an experimental animal model
Presenting Author: Agata Tomaszewska, Lodz, Poland

P04.13
Downregulation of pro-regenerative activity of IL-33 in the milieu of H. pylori lipopolysaccharide
Presenting Author: Weronika Gonciarz, Lodz, Poland

P04.14
ADP-heptose is the determinant of Helicobacter pylori responsible for the dampening of HLA-II expression in macrophages
Presenting Author: Marina de Bernard, Padova, Italy

P04.15
Pro-inflammatory and anti-inflammatory cytokines and immunoglobulins in the development of chronic atrophic gastritis with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P04.16
TLR1-SNP-rs4833095-genotype is not associated with inflammation phenotype in H.pylori-negative patients
Presenting Author: Alexander Link, Magdeburg, Germany

P04.17
Analysis of indicators characterizing the system immune response in patients with Helicobacter pylori
Presenting Author: Elizaveta Ageeva, Simferopol, Russian Federation

P04.18
Association between the Helicobacter pylori cagA virulence gene and the severity of gastroduodenal lesions
Presenting Author: Mônica Barbosa, Goiânia, Brazil

 


Electronic Poster Round 5: Epidemiology

P05.01
Relationship of alcohol and tobacco consumption and the development of gastric adenocarcinoma
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.02
Detection of Helicobacter suis in pork meat products aimed to human consumption
Presenting Author: Miguel García-Ferrús, Valencia, Spain

P05.03
Evaluation of the chemioprotective role of pequi fruit (Caryocar brasiliense) in gastric cancer.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.04
Prevalence of Helicobacter pylori infection in asymptomatic children from Southeastern Brazil
Presenting Author: Ana Carlos, Botucatu, Brazil

P05.05
Dietary patterns and Helicobacter pylori infection in dyspeptic patients in Central West Brazil.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.06
Differences in management of Helicobacter pylori infection: an observational study
Presenting Author: Ruffin Ntounda, bruxelles, Belgium

P05.07
Helicobacter pylori is associated with uninvestigated dyspepsia in inhabitants of the Eastern Siberia administrative center
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

P05.08
Relationship between food habits and the development of gastric adenocarcinoma.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.09
Gastric cancer early mortality: a brazilian cohort study
Presenting Author: Tatiane Tiengo, São Paulo, Brazil

P05.10
Prevalence of Helicobacter pylori cagA, vacA, oipA and iceA genotypes in Russian patients with gastroduodenal diseases
Presenting Author: Alena Svarval, Saint Petersburg, Russian Federation


Electronic Poster Round 6: Microbiology and genomics of Helicobacter

P06.01
Phenotypic, Molecular, and Whole Genome Characterization of Antibiotic Resistance in Enterohepatic Helicobacter species
Presenting Author: Anthony Mannion, Cambridge, United States

P06.02
Detection & genotyping of H. pylori in environmental samples
Presenting Author: Irene Hortelano Martin, Valencia, Spain

P06.03
Genetic diversity of Helicobacter pylori strains isolated from single patients using Multilocus Sequence Typing (MLST)
Presenting Author: Parastoo Saniee, Tehran, Iran, Islamic Republic of

P06.04
Potential role of single nucleotide polymorphism of gluP and cgt genes in H. pylori biofilm Formation
Presenting Author: Kartika Fauzia, Yufu, Oita, Japan

P06.05
Peptidoglycan as a marker for isolation of endosymbiotic Helicobacter pylori and Staphylococcus from yeast
Presenting Author: Samira Heydari, Tehran, Iran, Islamic Republic of

P06.06
Prophage elements in Greek Helicobacter pylori clinical isolates
Presenting Author: Beatriz Martinez-Gonzalez, Athens, Greece

P06.07
Helicobacter pylori ‘s type 4 secretion systems as a gastroduodenal diseases marker
Presenting Author: Bui Hoang Phuc, Yufu, Japan

P06.08
Comparative genomic analysis in Colombian Helicobacter pylori isolates: a focus to virulence, antibiotic resistance, and population structure.
Presenting Author: Johanna Stepanian-Rozo, Bogotá, Colombia

P06.09
Genetic diversity of vacA variable i , d and c regions in Helicobacter pylori isolates from individual hosts
Presenting Author: Parastoo Saniee, Tehran, Iran, Islamic Republic of

 

Electronic Poster Round 7: Helicobacter and extragastroduodenal diseases

P07.01
Mucus-degrading microbiota and proinflammatory T-cell responses underlie Helicobacter pylori induced colon carcinogenesis
Presenting Author: Anna Ralser, Munich, Germany

P07.02
Exploring the binding mechanisms of Helicobacter pylori to colon epithelial cells and induced downstream signaling
Presenting Author: Anna Ralser, Munich, Germany

P07.03
Circulating ghrelin decrease following Helicobacter pylori eradication
Presenting Author: Paula Mantero, Buenos Aires, Argentina

P07.04
Autoimmune disease did not result in a higher incidence of pernicious anemia among a cohort of 94 patients with active H. pylori infection presenting to a rheumatology clinic
Presenting Author: Michael Lovy, Palm Springs, United States

P07.05
Helicobacter pylori infection, monoclonal gammopathy of uncertain significance, and autoimmune disease in a cohort of 150 patients with pernicious anemia
Presenting Author: Michael Lovy, Palm Springs, United States

P07.06
Screening and diagnosis of Helicobacter pylori infection and autoimmune gastritis in patients with inflammatory bowel diseases
Presenting Author: Mila Kovacheva-Slavova, Sofia, Bulgaria

P07.07
Prevalence & impact of Helicobacter pylori in patients with cirrhosis
Presenting Author: Nouha Trad, Ariana, Tunisia

P07.08
The frequency of Helicobacter pylori and the structure of the gastric mucosa in elderly patients with esophagitis
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

P07.09
Comorbidity profile according to Helicobacter pylori infection status
Presenting Author: Mônica Barbosa, Goiânia, Brazil


EP08 Electronic Poster Round 8: Paediatric conditions

P08.01
Faecal microbiota in infants and toddlers with allergy
Presenting Author: Erika Luse, Riga, Latvia

P08.02
Cytokine profile in schoolchildren with Helicobacter pylori with familial burden of stomach cancer
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.03
Cytokine levels in Helicobacter pylori associated gastritis in children with familial burden of peptic ulcer disease
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.04
The course of Helicobacter pylori associated gastritis in schoolchildren of Buryatia
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.05
CK20 in gastric mucosa in children with Helicobacter pylori-associated gastritis with superimposed GERD
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.06
Expression of CK20 in the stomach in children with Helicobacter pylori and familial predisposition to peptic ulcer disease
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.07
CK7 in schoolchildren with Helicobacter pylori-associated gastritis
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

 

Electronic Poster Round 9: Gut microbiota and non-intestinal diseases

P09.01
Effects of indigenous fecal bacteria consortium treatment in patients with metabolic syndrome
Presenting Author: Konstantin Ermolenko, Saint-Petersburg, Russian Federation

 


EP10 Electronic Poster Round 10: Microbiota and intestinal diseases

P10.01
Double blind RCT study on the efficacy of L. reuteri 4659 in reducing inflammatory markers in patients affected by acute uncomplicated diverticulitis
Presenting Author: Veronica Ojetti, Rome, Italy

P10.02
Effects of cytokines in chronic gastroduoenitis associated with Helicobacter pylori, fungi and protozoa invasion
Presenting Author: Elena Agafonova, Kazan, Russian Federation

P10.03
Rifaximin for small intestinal bacterial overgrowth: a retrospective study
Presenting Author: Carolina Mosoni, Rome, Italy

P10.04
Gut microbiota modification in patients with inflammatory bowel diseases who do not received and received biological therapy
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

 

Electronic Poster Round 11: Microbiota and cancer

P11.01
Presence of colibactin-producing E.coli in biliary juice and development of cholangiocarcinoma
Presenting Author: Parastoo Saniee, Tehran, Iran, Islamic Republic of

P11.02
Bacteria-derived extracellular vesicles in urine as a novel biomarker for gastric cancer: integration of liquid biopsy and metagenome analysis
Presenting Author: Jae Gyu Kim, Seoul, Korea, Republic of

 

Electronic Poster Round 12: Gut microbiota manipulation

P12.01
Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during the Helicobacter pylori eradication therapy
Presenting Author: Sara Cifuentes, Quito, Ecuador

P12.02
Original article. Fecal microbiome transplantation for recurrent CDI treatment: efficacy, short and long-term follow-up results from consecutive case series.
Presenting Author: Tadas Urbonas, Kaunas, Lithuania

 

Electronic Poster Round 13: Microbiota detection and analyses

P13.01
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol associated liver disease
Presenting Author: Dionisi Tommaso, Rome, Italy

P13.02
Gut bacteria functionality profiles and diversity index detected by the GA-map® Dysbiosis Test Lx
Presenting Author: Kristin Gravdal, Oslo, Norway

P13.03
Effects of green tea and post-fermented green tea extract on obese adults: a randomized double-blind, placebo-controlled trial focused on change of gut microbiota
Presenting Author: MUNJIN JU, Seongnam, Gyeonggi, Korea, Republic of

P13.04
A portable H2-breath tracker: laboratory assessment.
Presenting Author: Elena Kolomina, St. Petersburg, Russian Federation

2021 EHMSG - Abstractbook FIN_Seite_001 WEB.png

Click to view the
EHMSG 2021 Abstractbook